TherapeuticsMD TXMD will be releasing its next round of earnings Tuesday. For all of the relevant information, here is your guide for today's Q4 earnings announcement.
Earnings and Revenue
Wall Street expects an earnings loss of 9 cents per share and sales around $4.6 million.
In the same quarter last year, TherapeuticsMD posted a loss of 12 cents per share on sales of $4 million. If the company were to match the consensus estimate, earnings would be down 25.00 percent. Revenue would be have grown 3.86 percent from the same quarter last year.
Here's how the company's reported EPS has compared to analyst estimates in the past:
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | -0.11 | -0.11 | -0.11 | -0.12 |
| EPS Actual | -0.07 | -0.1 | -0.11 | -0.12 |
Stock Performance
Over the last 52-week period, shares are down 3.13 percent. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
Over the past 90 days, analysts' have adjusted their estimates higher for EPS and revenues. The most common rating from analysts on TherapeuticsMD stock is a Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
TherapeuticsMD's Q4 is scheduled to hold a conference call at 4:30 p.m. ET and it can be accessed here: https://ir.therapeuticsmd.com/events/event-details/q4-2017-therapeuticsmd-inc-earnings-conference-call
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
